Thomas P. Loughran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas P. Loughran has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
David J. Feith
Department of Medicine, Division of Hematology and Oncology University of Virginia School of Medicine, Charlottesville, VA
3 shared publicationsBin Pan
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China; The Key Laboratory of Transplantation Immunity, Affiliated Hospital of Xuzhou Medical University, Jiangsu Province, China
2 shared publicationsCai Sun
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China; The Key Laboratory of Transplantation Immunity, Affiliated Hospital of Xuzhou Medical University, Jiangsu Province, China
2 shared publicationsCong Zhang
Department of hematology, Huaibei miners General Hospital, Anhui Province, China
2 shared publicationsDavid F. Claxton
Penn State Hershey Cancer Institute Hershey, PA
2 shared publicationsDhimant Desai
Departments of Pharmacology Pennsylvania State University College of Medicine, Hershey, PA
2 shared publications
Latest Publications
- 1 September 2019
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 32 (3) , 193-195
Large granular lymphocytic and other rare lymphoid leukemias
- 1 September 2019
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 32 (3) , 193-195
Large granular lymphocytic and other rare lymphoid leukemias
- Open Access
- 1 June 2019
- Published by Elsevier in Journal of Lipid Research
- Vol. 60 (6) , 1078-1086
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation
- 1 June 2019
- Published by Elsevier in Journal of Lipid Research
- Vol. 60 (6) , 1078-1086
Open AccessAcid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation
- 8 December 2017
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2017 (1) , 181-186
Chronic neutropenia in LGL leukemia and rheumatoid arthritis
This section reviews the diagnostic criteria and pathogenesis of large granular lymphocyte (LGL) leukemia. There is a particular focus on the overlap of LGL leukemia and rheumatoid arthritis (Felty's syndrome). Current understanding of the mechanisms of neutropenia in these disorders is discussed. Finally, treatment indications and therapeutic recommendations are outlined.
- 8 December 2017
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2017 (1) , 181-186
Chronic neutropenia in LGL leukemia and rheumatoid arthritis
This section reviews the diagnostic criteria and pathogenesis of large granular lymphocyte (LGL) leukemia. There is a particular focus on the overlap of LGL leukemia and rheumatoid arthritis (Felty's syndrome). Current understanding of the mechanisms of neutropenia in these disorders is discussed. Finally, treatment indications and therapeutic recommendations are outlined.
- 2 May 2017
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 21 (6) , 583-590
The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia
Introduction: Acute myeloid leukemia (AML) is the most common adult leukemia. Only a fraction of AML patients will survive with existing chemotherapy regimens. Hence, there is an urgent and unmet need to identify novel targets and develop better therapeutics in AML. In the past decade, the field of sphingolipid metabolism has emerged into the forefront of cancer biology due to its importance in cancer cell proliferation and survival. In particular, acid ceramidase (AC) has emerged as a promising therapeutic target due to its role in neutralizing the pro-death effects of ceramide. Areas covered: This review highlights key information about AML biology as well as current knowledge on dysregulated sphingolipid metabolism in cancer and AML. We describe AC function and dysregulation in cancer, followed by a review of studies that report elevated AC in AML and compounds known to inhibit the enzyme. Expert opinion: AML has a great need for new drug targets and better therapeutic agents. The finding of elevated AC in AML supports the concept that this enzyme represents a novel and realistic therapeutic target for this common leukemia. More effort is needed towards developing better AC inhibitors for clinical use and combination treatment with existing AML therapies.
- 2 May 2017
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 21 (6) , 583-590
The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia
Introduction: Acute myeloid leukemia (AML) is the most common adult leukemia. Only a fraction of AML patients will survive with existing chemotherapy regimens. Hence, there is an urgent and unmet need to identify novel targets and develop better therapeutics in AML. In the past decade, the field of sphingolipid metabolism has emerged into the forefront of cancer biology due to its importance in cancer cell proliferation and survival. In particular, acid ceramidase (AC) has emerged as a promising therapeutic target due to its role in neutralizing the pro-death effects of ceramide. Areas covered: This review highlights key information about AML biology as well as current knowledge on dysregulated sphingolipid metabolism in cancer and AML. We describe AC function and dysregulation in cancer, followed by a review of studies that report elevated AC in AML and compounds known to inhibit the enzyme. Expert opinion: AML has a great need for new drug targets and better therapeutic agents. The finding of elevated AC in AML supports the concept that this enzyme represents a novel and realistic therapeutic target for this common leukemia. More effort is needed towards developing better AC inhibitors for clinical use and combination treatment with existing AML therapies.
- Open Access
- 4 November 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (50) , 83208-83222
Acid ceramidase is upregulated in AML and represents a novel therapeutic target
Acid ceramidase is upregulated in AML and represents a novel therapeutic target Acid ceramidase is upregulated in AML and represents a novel therapeutic target
- 4 November 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (50) , 83208-83222
Open AccessAcid ceramidase is upregulated in AML and represents a novel therapeutic target
Acid ceramidase is upregulated in AML and represents a novel therapeutic target Acid ceramidase is upregulated in AML and represents a novel therapeutic target
- 1 August 2016
- Published by Elsevier in Cellular Immunology
- Vol. 306-307, 35-40
MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway
- 1 August 2016
- Published by Elsevier in Cellular Immunology
- Vol. 306-307, 35-40
MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway
- 1 April 2016
- Published by Elsevier in Immunology Letters
- Vol. 172, 1-10
MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway
- 1 April 2016
- Published by Elsevier in Immunology Letters
- Vol. 172, 1-10
MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway
- 24 June 2015
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 7 (293) , 293ra102
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
Epigenetic drugs can overcome resistance to monoclonal antibodies in T-PLL and activate therapeutic targets for antibody-drug conjugates.
- 24 June 2015
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 7 (293) , 293ra102
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
Epigenetic drugs can overcome resistance to monoclonal antibodies in T-PLL and activate therapeutic targets for antibody-drug conjugates.
- 13 September 2014
- Published by Springer Nature in Leukemia
- Vol. 29 (4) , 886-894
Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)
Failure to undergo activation-induced cell death due to global dysregulation of apoptosis is the pathogenic hallmark of large granular lymphocyte (LGL) leukemia. Consequently, immunosuppressive agents are rational choices for treatment. This first prospective trial in LGL leukemia was a multicenter, phase 2 clinical trial evaluating methotrexate (MTX) at 10 mg/m2 orally weekly as initial therapy (step 1). Patients failing MTX were eligible for treatment with cyclophosphamide at 100 mg orally daily (step 2). The overall response in step 1 was 38% with 95% confidence interval (CI): 26 and 53%. The overall response in step 2 was 64% with 95% CI: 35 and 87%. The median overall survival for patients with anemia was 69 months with a 95% CI lower bound of 46 months and an upper bound not yet reached. The median overall survival for patients with neutropenia has not been reached 13 years from study activation. Serum biomarker studies confirmed the inflammatory milieu of LGL but were not a priori predictive of response. We identify a gene expression signature that correlates with response and may be STAT3 mutation driven. Immunosuppressive therapies have efficacy in LGL leukemia. Gene signature and mutational profiling may be an effective tool in determining whether MTX is an appropriate therapy.
- 13 September 2014
- Published by Springer Nature in Leukemia
- Vol. 29 (4) , 886-894
Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)
Failure to undergo activation-induced cell death due to global dysregulation of apoptosis is the pathogenic hallmark of large granular lymphocyte (LGL) leukemia. Consequently, immunosuppressive agents are rational choices for treatment. This first prospective trial in LGL leukemia was a multicenter, phase 2 clinical trial evaluating methotrexate (MTX) at 10 mg/m2 orally weekly as initial therapy (step 1). Patients failing MTX were eligible for treatment with cyclophosphamide at 100 mg orally daily (step 2). The overall response in step 1 was 38% with 95% confidence interval (CI): 26 and 53%. The overall response in step 2 was 64% with 95% CI: 35 and 87%. The median overall survival for patients with anemia was 69 months with a 95% CI lower bound of 46 months and an upper bound not yet reached. The median overall survival for patients with neutropenia has not been reached 13 years from study activation. Serum biomarker studies confirmed the inflammatory milieu of LGL but were not a priori predictive of response. We identify a gene expression signature that correlates with response and may be STAT3 mutation driven. Immunosuppressive therapies have efficacy in LGL leukemia. Gene signature and mutational profiling may be an effective tool in determining whether MTX is an appropriate therapy.